Investors sold shares of Merck & Company, Inc. (NYSE:MRK) on strength during trading on Monday. $47.54 million flowed into the stock on the tick-up and $126.67 million flowed out of the stock on the tick-down, for a money net flow of $79.13 million out of the stock. Of all equities tracked, Merck & had the 6th highest net out-flow for the day. Merck & traded up $0.48 for the day and closed at $61.97

A number of analysts have recently issued reports on the stock. HSBC Holdings plc upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “sell” rating and issued a $52.00 price objective on shares of Merck & in a report on Sunday. BidaskClub downgraded shares of Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. UBS AG lifted their price objective on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a report on Monday, July 31st. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $74.00 price objective on shares of Merck & in a report on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. Merck & currently has an average rating of “Hold” and an average target price of $69.63.

The company’s 50-day moving average is $62.91 and its 200-day moving average is $63.83. The company has a market cap of $169.01 billion, a PE ratio of 33.55 and a beta of 0.80.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. During the same quarter last year, the firm posted $0.93 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is currently 76.11%.

Large investors have recently made changes to their positions in the company. Sentry Investment Management LLC raised its stake in shares of Merck & by 1.1% in the second quarter. Sentry Investment Management LLC now owns 219,405 shares of the company’s stock valued at $14,062,000 after buying an additional 2,333 shares during the period. WFG Advisors LP raised its stake in shares of Merck & by 16.9% in the second quarter. WFG Advisors LP now owns 13,478 shares of the company’s stock valued at $864,000 after buying an additional 1,946 shares during the period. Toronto Dominion Bank raised its stake in shares of Merck & by 22.4% in the second quarter. Toronto Dominion Bank now owns 1,019,846 shares of the company’s stock valued at $65,359,000 after buying an additional 186,774 shares during the period. Afam Capital Inc. raised its stake in shares of Merck & by 14.5% in the second quarter. Afam Capital Inc. now owns 36,755 shares of the company’s stock valued at $2,356,000 after buying an additional 4,667 shares during the period. Finally, Beaton Management Co. Inc. purchased a new stake in shares of Merck & during the second quarter valued at $1,143,000. 73.46% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Investors Sell Shares of Merck & Company, Inc. (MRK) on Strength (MRK)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/21/investors-sell-shares-of-merck-company-inc-mrk-on-strength-mrk.html.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.